A Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Single Ascending Doses and Multiple Doses of AHB-137 in Healthy Participants and HBeAg-negative CHB Patients Receiving Stable Nucleos(t)Ide Analogues (NAs) Treatment
Latest Information Update: 25 Apr 2025
At a glance
- Drugs AHB 137 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AusperBio
- 11 Feb 2025 According to an AusperBio media release, interim Phase IIa study data presented in a late-breaking oral presentation at the 2024 AASLD Liver Meeting.
- 05 Nov 2024 Status changed from recruiting to active, no longer recruiting.
- 07 Aug 2024 Phase of study changed from phase 1 to phase1/2, treatment arms changed from 2 to 3